JUNSHI BIO (01877) has released an announcement revealing that in the first three quarters of 2026, the company recorded operating revenue of RMB 2.513 billion, representing a year-on-year increase of 39.18%.
The net loss attributable to shareholders of the listed company stood at RMB 149 million, narrowing by 75% compared with the same period last year.
Basic loss per share was RMB 0.15.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments